ArticleOpen forum infectious diseases2026
Impact of Methicillin Resistance on Outcomes of
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methicillin-resistant Methods: We conducted a retrospective cohort study of adults with a first-episode SAB at two academic hospitals from January 17, 2023 to January 16, 2024. The primary outcome of in-hospital mortality/hospice discharge was compared between MRSA and MSSA. Secondary outcomes included intensive care unit (ICU) admission, 7-day readmission, metastatic complications, infective endocarditis, and recurrent bacteremia. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs), with propensity score matching as sensitivity analysis. Results: Among 329 patients with SAB, 140 (42.6%) had MRSA and 189 (57.4%) had MSSA. Compared with MSSA, MRSA was associated with younger age, lower body mass index, higher injection drug use prevalence, more skin and soft tissue sources, and lower illness severity. After covariate adjustment, methicillin resistance was not associated with mortality/hospice discharge (aOR 1.03, 95% CI 0.49-2.12), ICU admission (aOR 1.09, 95% CI 0.61-1.94), 7-day readmission (aOR 1.51, 95% CI 0.51-4.67), metastatic complications (aOR 0.98, 95% CI 0.47-2.05), infective endocarditis (aOR 1.02, 95% CI 0.42-2.45), or recurrent bacteremia (aOR 2.43, 95% CI 0.92-6.76). Findings were consistent in propensity-matched analyses. Conclusions: In this contemporary academic cohort, methicillin resistance was associated with distinct patient characteristics but not worse short-term outcomes. Host factors, illness severity, and infection source may be more important prognostic determinants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.